524 Results

EU approves new subcutaneous form of lupus treatment

 Added 6 days ago

The European Commission has approved a new subcutaneous formulation of Benlysta (belimumab), from GSK, as an add-on therapy in adult...

Phase III SPIRIT extension study shows Taltz improvements for psoriatic arthritis - Eli Lilly.

 Added 11 days ago

Eli Lilly and Company announced patients with active psoriatic arthritis (PsA) treated with Taltz (ixekizumab), who were previously intolerant or...

FDA accepts NDA for IDP 118, a topical treatment for plaque psoriasis.- Ortho Dermatologics/Valeant.

 Added 17 days ago

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced that the FDA has accepted the New Drug Application (NDA)...

World Psoriasis Day 2017

 Added 24 days ago

World Psoriasis Day 2017

Psoriasis inside out is the theme of this year’s World Psoriasis Day

9th Clinical Dermatology Congress

 Added 1 month ago

Breakthrough to Excellence in Clinical Dermatology, October 16–18 2017 in New York.

FDA approves expended indication for Stelara (ustekinumab) in moderate to severe plaque psoriasis.- Janssen Biotech.

 Added 1 month ago

Janssen Biotech announced that the FDA has approved an expanded indication for Stelara (ustekinumab) for the treatment of adolescents (12...

AMAGINE-2 Phase III extension study shows two year positive results for Siliq (brodalumab injection) as a treatment of psoriasis.- Ortho Dermatologics.

 Added 1 month ago

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. announced results from the pivotal Phase III long-term extension study (AMAGINE-2),...

Three sub-analyses from the Phase III OASIS-1 study show a consistent safety/efficacy profile of omadacycline, when treating (ABSSSI) in patients with comorbid conditions.- Paratek Pharmaceuticals.

 Added 1 month ago

Paratek Pharmaceuticals announced the results of three sub-analyses from the Phase III OASIS-1 study that show a consistent safety and...

REVIVE-2, a global Phase III clinical trial has success in evaluating iclaprim in patients with acute bacterial skin and skin structure infections.- Motif Bio.

 Added 1 month ago

Motif Bio plc announced positive topline results from REVIVE-2, a global Phase III clinical trial evaluating the investigational drug candidate...

EU Commission approves Dupixent (dupilumab) to treat in adults with moderate-to-severe atopic dermatitis .- Sanofi + Regeneron.

 Added 1 month ago

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for Dupixent (dupilumab), for use in...

Load more